Peptide-based passive immunization therapy for treatment of atherosclerosis
AssigneeForskarpatent I Syd AB
InventorsJan Nilsson, Roland Carlsson, Jenny Bengtsson, Leif Strandberg
Life of this patent
Estimating the term…
Abstract
The present invention relates to passive immunization for treating or preventing atherosclerosis using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B in the manufacture of a pharmaceutical composition for therapeutical or prophylactical treatment of atherosclerosis by means of passive immunization, as well as method for preparing such antibodies, and a method for treating a mammal, preferably a human using such an antibody to provide for passive immunization.
Claims51
Use of at least one recombinant human antibody or antibody fragment directed towards at least one oxidized fragment of apolipoprotein B in the manufacture of a pharmaceutical composition for therapeutical or prophylactical treatment of atherosclerosis by means of passive immunization.
Antibodies raised against fragments of apo B100 comprising a variable heavy region (VH) selected from the group of nucleic acid sequences consisting of
- (SEQ. ID. NO. 1)
- (SEQ. ID. NO. 3)
- (SEQ. ID. NO. 5)
- (SEQ. ID. NO. 7)
- (SEQ. ID. NO. 9)
- (SEQ. ID. NO. 11)
- (SEQ. ID. NO. 19)
- (SEQ. ID. NO. 21)
- (SEQ. ID. NO. 23)
- (SEQ. ID. NO. 25)
- (SEQ. ID. NO. 27)
- (SEQ. ID. NO. 29)
- (SEQ. ID. NO. 31)
- (SEQ. ID. NO. 33)
- (SEQ. ID. NO. 35)
- (SEQ. ID. NO. 37)
- in combination with a variable light region (VL) selected from the group of nucleic acid sequences consisting of
- (SEQ. ID. NO. 2)
- (SEQ. ID. NO. 4)
- (SEQ. ID. NO. 6)
- (SEQ. ID. NO. 8)
- (SEQ. ID. NO. 10)
- (SEQ. ID. NO. 12)
- (SEQ. ID. NO. 20)
- (SEQ. ID. NO. 22)
- (SEQ. ID. NO. 24)
- (SEQ. ID. NO. 26)
- (SEQ. ID. NO. 28)
- (SEQ. ID. NO. 30)
- (SEQ. ID. NO. 32)
- (SEQ. ID. NO. 34)
- (SEQ. ID. NO. 36)
- (SEQ. ID. NO. 38)
Method for passive immunization of mammals, preferably humans, wherein a therapeutically or prophylactically effective amount of a isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B is administered for treatment of atherosclerosis.
A pharmaceutical composition comprising an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B for therapeutical or prophylactical treatment of atherosclerosis by means of passive immunization, which antibody is present in combination with a pharmaceutical excipient.
Dependencies are inferred from the claim text.